Physician profile
Brian E Gaupp
NPI 1649265430
$1,157.81
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $183 · 2020: $11.91 · 2021: $268 · 2022: $339 · 2023: $356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $356.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $355.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $141.25 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $127.52 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $92.86 | 2019-2022 | |
| Janssen Biotech, INC. | $87.73 | 2021-2023 | Darzalex, Tecvayli |
| Genzyme Corporation | $74.25 | 2022-2023 | |
| Gilead Sciences, INC. | $73.46 | 2021-2023 | Trodelvy |
| Astrazeneca Pharmaceuticals Lp | $60.24 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $50.65 | 2022-2023 | Ninlaro |
| Regeneron Healthcare Solutions, INC. | $44.85 | 2022-2023 | Libtayo |
| Glaxosmithkline, LLC. | $36.74 | 2021-2023 | |
| Alexion Pharmaceuticals, INC. | $34.50 | 2019-2021 | |
| Exelixis INC. | $32.62 | 2021-2022 | |
| Eisai INC. | $31.33 | 2019-2022 | |
| Rigel Pharmaceuticals, INC. | $28.81 | 2021-2023 | Tavalisse, Rezlidhia |
| Genentech USA, INC. | $27.78 | 2019-2023 | Venclexta |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $27.61 | 2019-2021 | |
| Celgene Corporation | $27.61 | 2019-2022 | |
| Pfizer INC. | $25.89 | 2021-2023 | |
| Veran Medical Technologies, INC. | $22.38 | 2019 | |
| Myriad Genetic Laboratories, INC. | $19.39 | 2023 | Precisetumor |
| Stemline Therapeutics INC. | $18.64 | 2023 | Orserdu |
| Seagen INC. | $16.41 | 2022 | |
| Dova Pharmaceuticals | $16.20 | 2019 | |
| Array Biopharma INC | $14.21 | 2022 | |
| Mirati Therapeutics, INC. | $12.97 | 2023 | Krazati |
| Astellas Pharma US INC | $11.91 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Gaupp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.